CS
AVDL

Credit Suisse’s Avadel Pharmaceuticals AVDL Stock Holding History

Credit Suisse’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,804
Closed -$87K – 4149
2019
Q3 		$87K Sell
20,804
-30,968
-60% -$77.5K ﹤0.01% 3983
2019
Q2 		$150K Buy
51,772
+33,171
+178% +$57K ﹤0.01% 3893
2019
Q1 		$27K Buy
+18,601
New +$42.1K ﹤0.01% 3930
2017
Q1 		– Sell
-28,931
Closed -$301K – 3802
2016
Q4 		$301K Sell
28,931
-3,093
-10% -$34K ﹤0.01% 3663
2016
Q3 		$398K Buy
32,024
+3,872
+14% +$50.6K ﹤0.01% 3536
2016
Q2 		$303K Sell
28,152
-24,179
-46% -$258K ﹤0.01% 3685
2016
Q1 		$578K Buy
52,331
+40,828
+355% +$406K ﹤0.01% 3144
2015
Q4 		$140K Sell
11,503
-2,480
-18% -$38.7K ﹤0.01% 4012
2015
Q3 		$228K Sell
13,983
-25,501
-65% -$562K ﹤0.01% 3861
2015
Q2 		$836K Buy
39,484
+9,251
+31% +$166K ﹤0.01% 3335
2015
Q1 		$543K Sell
30,233
-9,471
-24% -$148K ﹤0.01% 3491
2014
Q4 		$681K Buy
39,704
+24,491
+161% +$350K ﹤0.01% 3473
2014
Q3 		$218K Buy
15,213
+769
+5% +$11.1K ﹤0.01% 4094
2014
Q2 		$217K Buy
+14,444
New +$174K ﹤0.01% 4297

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse's AVDL Position: Q4 2019 in Review

Credit Suisse sold out of Avadel Pharmaceuticals (AVDL) in Q4 2019, closing a stake of 20,804 shares — an estimated $87K sold.

Credit Suisse first reported a position in AVDL in Q2 2014 and held it in 14 quarters. The position peaked at $836K in Q2 2015. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

  • Credit Suisse reported no remaining Avadel Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 20,804 Avadel Pharmaceuticals shares in Q4 2019, an estimated $87K.
  • Credit Suisse first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 14 quarters.
  • Credit Suisse's Avadel Pharmaceuticals position peaked at $836K in Q2 2015.
  • 42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.